<DOC>
	<DOCNO>NCT03016611</DOCNO>
	<brief_summary>To examine efficacy chew Ticagrelor versus Prasugrel ST-elevation Myocardial Infarction ( STEMI ) patient platelet reactivity .</brief_summary>
	<brief_title>Chewing Ticagrelor Versus Prasugrel ST-elevation Myocardial Infarction - A Platelet Reactivity Study</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Patients present STEMI 2 . Informed , write consent 1 . Age &lt; 18 year Age &gt; 75 year 2 . Active bleeding ; bleed diathesis ; coagulopathy 3 . Increased risk bradycardic event 4 . History gastrointestinal genitourinary bleeding &lt; 2 month 5 . Major surgery last 6 week 6 . History intracranial bleed structural abnormality 7 . Suspected aortic dissection 8 . Any condition may put patient risk influence study result investigator 's opinion ( severe hemodynamic instability , unconsciousness , know malignancy comorbid condition life expectancy &lt; 1 year ) 9 . Administration week index event clopidogrel , ticlopidine , prasugrel , ticagrelor , thrombolytic , bivalirudin , lowmolecular weight heparin fondaparinux . 10 . Concomitant oral IV therapy strong CYP3A inhibitor strong CYP3A inducer , CYP3A narrow therapeutic window 11 . Known relevant hematological deviation : Hb &lt; 10 g/dl , PLT &lt; 100x10^9/l 12 . Use coumadin derivative within last 7 day 13 . Chronic therapy ticagrelor , prasugrel , clopidogrel ticlopidine 14 . Known severe liver disease , severe renal failure 15 . Known allergy study medication 16 . Pregnancy 17 . Human immunodeficiency virus treatment 18 . The use IIBIIIA receptor antagonists 48 hour enrollment ( abciximab use last 14 day ) . 19 . If patient sign percutaneous coronary intervention ( PCI ) inform consent reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>